Withdrawal of antipsychotic drugs from adults with intellectual disabilities

Irish Journal of Psychological Medicine

Volumn 21, Issue 3, 2004, Pages 85-90

  Stevenson, Claire ^a   Rajan, Lovely ^b   Reid, Gavin ^c   Melville, Craig ^d   McGilp, Robin ^b   Cooper, Sally Ann ^d  

^a W of Scotland Higher Train Scheme   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c S E Scotland Higher Train Scheme   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antipsychotic drugs; Health service economics; Intellectual disabilities; Mental retardation

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUTISM; BEHAVIOR DISORDER; COST OF ILLNESS; DISEASE SEVERITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENDER; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONEY; OUTCOMES RESEARCH; PERSONALITY DISORDER; PSYCHOSIS; SEDATION; SEX DIFFERENCE; SIDE EFFECT; UNITED KINGDOM; VERBAL COMMUNICATION;

EID: 11844269286     PISSN: 07909667     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0790966700008417     Document Type: Article

References (19)

1. Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 1986; 43: 335-340
2. Manchester D. Neuroleptics, learning disabilities and the community: some history and mystery. BMJ 1993; 307: 184-187
3. Robertson J, Emerson E, Gregory N, Hatton C, Kessissiglou S, Hallam A. Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellectual Disability Res 2002; 44: 666-676
4. Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities J Intellectual Disability Research 1996; 40: 322-329
5. Ahmed Z, Fraser W, Kerr MP et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiat 2000; 176: 42-46
6. Molyneaux P, Emerson E, Caine A. Prescription of psychotropic medication to people with intellectual disabilities in primary health care settings. J App Res Intellectual Disability 2000; 12: 46-57
7. May P, London EB, Zimmerman T, Thompson R, Mento AB, Spreat S. A study of the clinical outcomes of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 1995; 7: 155-160.
8. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability: a systematic review of randomised controlled trials. J Intellectual Disability Res 1999; 43: 360-371
9. Department of Health Thioridazine: restricted indications and new warnings on cardiotoxicity, 28/111/12/2000, cem/cmo/2000/18. Department of Health: London, 2000
10. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTC interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-1052.
11. Hennessy S, Bilker Wb, Knauss JS et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070-1072
12. Reilly JG, Ayis A, Ferrier N, Jones SJ, Thomas SHL. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiat 2002; 180: 515-522
13. Davies, SJC, Cooke LB, Moore AG, Potokar J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 1519-1521
14. Arshad P, Morcos M, Stidharan B. Discontinuation of thioridazine: what happened to thioridazine? BMJ 2002; 325: 968
15. Royal College of Psychiatrists DC-LD [Diagnostic Criteria for Psychiatric Disorders for use with Adults with Learning Disabilities/Mental Retardation]. London: Gaskell Press, 2001
16. Netton A, Rees T, Harrison G. Unit Costs of Health and Social Care. PSSRU: University of Kent at Canterbury, 2001
17. Bisset AF. Discontinuation of thioridazine: risks must be balanced. BMJ 2002; 325, 967-968
18. Smith C, Felce D, Ahmed Z et al. Sedation effects on responsiveness: evaluating the reduction of antipsychotic medication in people with intellectual disability using a conditional probability approach. J Intellectual Disability Res 2002; 46: 464-471
19. Turner TH. Schizophrenia and mental handicap: an historical review, with implications for further research. Psych Med 1989; 19: 301-314